AstraZeneca has announced that ticagrelor, an oral antiplatelet medicine, received a class I recommendation from the European Society of Cardiology (ESC) in the revised “Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)” guidelines. Ticagrelor is known as Brilique in the European Union and Brilinta elsewhere.
Results of a landmark clinical trial, PROTECT, presented for the first time at the 2012 European Society of Cardiology (ESC) Congress, confirm the long-term safety of drug-eluting stents in the treatment of coronary artery disease in real-world clinical practice.
A novel non-invasive device which separates healthy and damaged heart muscle and restores ventricle function improves three-year outcomes in patients with ischaemic heart failure, according to research presented at the ESC Congress 2012 in Munich, Germany. The findings were presented by William T Abraham at an ESC press conference on 25 August and by Marco Costa at an ESC Congress scientific session on 27 August.
Abbott has announced that its Xience Xpedition Everolimus Eluting Coronary Stent System received CE mark for the treatment of coronary arterial disease. The company is launching the product immediately in CE mark countries.
Vascular Solutions has announced that it has acquired the Venture wire control catheter, a deflectable-tip catheter used to provide guidewire directional control in challenging coronary and peripheral interventional procedures, from St Jude Medical.
Transcatheter aortic valve implantation (TAVI) is a new technique with the potential for transforming the treatment of high-risk patients with aortic stenosis. Expansion and refinement of transcatheter approaches for aortic valve implantation is an area of active research and development. While a variety of transcatheter valves are currently in the pipeline, the Edwards Sapien and Medtronic CoreValve represent the two currently established devices in Europe, and both have been reported to have excellent flow characteristics.
Cardionovum has announced that it expects to launch in Europe, in the fourth quarter of 2012, its Prolimus Biograde, a next-generation sirolimus-eluting coronary stent system, which is designed to optimise long-term patient results.
Arterial Remodeling Technologies (ART) has reported the successful first-in-human implantation of its novel biodegradable stent. The case is part of the ARTDIVA (Arterial remodeling transient dismantling vascular angioplasty) clinical trial.
Cumulative radiation exposure to both patients and operators has become a topic of great interest given the overall increased use of both cardiovascular and non-cardiovascular imaging modalities. This is all the more important with the increasing usage of multimodality imaging, including non-invasive (single-photon emission computed tomography, computed tomography angiography) and invasive procedures in patients with known or suspected coronary artery disease.
With its 10-year anniversary and exceeding 50,000 implantations worldwide, transcatheter aortic valve implantation (TAVI) has proven to be a viable and safe treatment strategy for patients with severe aortic stenosis and high operative risk. However, with the prospect of treating younger or less sick patients, a number of vexing issues remain.
Abbott has announced its financial results for the second quarter ended June 30, 2012. Reported sales increased 2.0 percent, including an unfavourable 4.7 percent effect of foreign exchange
Canadian company CellAegis Devices, Inc., has announced that it has received a CE Mark for its autoRIC™ Device, which the company says for the first time allows simple, consistent, reliable and cost-effective automation of remote ischemic conditioning (RIC) at the point of care
Sexual dysfunction may be a marker of cardiovascular disease in men with longstanding type 1 diabetes, investigators announced at the 72nd Scientific Sessions of the American Diabetes Association (ADA).
Women with severe aortic stenosis appear to derive more benefit from transcatheter aortic valve implantation (TAVI) than their male counterparts, researchers found.
For patients with symptomatic severe aortic stenosis who are at high risk for surgical complications, both transcatheter aortic valve implantation (TAVI) and surgical replacement dramatically improve health status within 1 year, an analysis of the PARTNER trial showed.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos